Date:11/7/2008

Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 950 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit http://www.emdserono.com.

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of Euro 7.1 billion in 2007, a history that began in 1668, and a future shaped by 32,458 employees in 59 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merck.de.

'/>"/>

SOURCE EMD Serono, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
2. Merck Serono Named as a Top Employer by Science Magazine
3. EMD Serono Named as a Top Employer by Science Magazine
4. EMD Serono to Adopt Revised and Strengthened PhRMA Code
5. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
6. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
7. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
8. SkinMedica Launches TNS Essential Serum(TM)
9. Genesis Pharmaceuticals Launches New Corporate Website
10. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
11. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City